Desmopressin for Reversal of Antiplatelet Drugs in Stroke Due to Haemorrhage
Status:
Recruiting
Trial end date:
2022-01-14
Target enrollment:
Participant gender:
Summary
Haemorrhagic stroke, an emergency caused by bleeding in the brain, often leads to death or
long-term disability. A quarter of these patients are taking blood-thinning drugs
(antiplatelet drugs, such as aspirin) because they are at risk of a heart attack or ischaemic
stroke. Patients taking these drugs are more likely to die or be disabled if they have a
haemorrhagic stroke. At present, there is no effective treatment for reversing their effects.
Desmopressin is a drug which may reverse the effects of antiplatelet drugs and stop bleeding.
The investigators would like to run a large randomised trial to see if Desmopressin can
reduce the number of people who die or are disabled after haemorrhagic stroke.
Phase:
Phase 2
Details
Lead Sponsor:
University of Nottingham
Collaborator:
National Institute for Health Research, United Kingdom